Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 7/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 5/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9971755 | 0.89 | ACHE (0.46) | KDM4EMEN1KMT2AACHEDHODH | |
| SCHEMBL840416 | 0.87 | CLK1 (0.51) | KDM4EMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL16905530 | 0.85 | ACHE (0.49) | KDM4EMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL72366 | 0.80 | ADORA3 (0.45) | ACHEDHODHBCHEGRIN1GRIN2A | |
| SCHEMBL16767246 | 0.78 | HTT (0.59) | MEN1KMT2AACHEAPPDCPS | |
| SCHEMBL861205 | 0.78 | CYP1A1 (0.50) | KDM4EMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL72801 | 0.78 | DCPS (0.64) | KDM4EKMT2ASMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL29583288 | 0.78 | DCPS (0.64) | KDM4EKMT2ASMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL28041579 | 0.77 | DHODH (0.49) | KDM4EMEN1KMT2AACHEDHODH | |
| SCHEMBL27223540 | 0.77 | DCPS (0.53) | KDM4EKMT2ADCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122916-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8129402-B2 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-06 | — | — | US | disclosed |
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ) (FR) | 2007-02-08 | — | — | US | disclosed |
| EP-1551992-B1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NAT RECH SCIENT (FR) | 2006-12-27 | — | — | EP | disclosed |
| US-20060172337-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1551992-A2 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035813-A2 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122916-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | PRPF6, PRNP, TDP1 | KDM4E 3738/4885MEN1 3396/4885KMT2A 4202/4885 |
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | ATXN2L, ATXN10, CLN6 | KDM4E 2700/4885MEN1 3486/4885KMT2A 3374/4885 |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | ATXN2L, ATXN10, CLN6 | KDM4E 2700/4885MEN1 3486/4885KMT2A 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.